Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05372354 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 17
- Study locations
NCT05372354: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT05372354 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (52% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05372354, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Trametinib
- DRUG Tazemetostat
- DRUG CC-92480
- DRUG BMS-986158
Study Locations (17)
Other
- ICO - Hospital Germans Trias i Pujol - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Marques de Valdecilla - Santander
- NIHR UCLH Clinical Research Facility - London
Alberta
- Alberta Health Services AHS - Foothills Medical Centre FMC - Calgary
- University of Alberta - Cross Cancer Institute - Edmonton
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Maryland
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
New York
- Memorial Sloan Kettering Cancer Center - New York
Ontario
- University Health Network UHN - Princess Margaret Hospital PMH - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2026-10-12 |
| Phase | Phase 1 |
What NCT05372354 shows while recruiting
NCT05372354 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT05372354 lists 17 locations in 13 states (Other, Alberta, Alabama).
Frequently Asked Questions
What is clinical trial NCT05372354 about?
NCT05372354 is a clinical study titled "A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
What is the current status of trial NCT05372354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2022-10-18. Estimated completion is 2026-10-12.
What conditions does trial NCT05372354 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05372354?
The interventions under investigation include: Dexamethasone (DRUG), Trametinib (DRUG), Tazemetostat (DRUG), CC-92480 (DRUG), BMS-986158 (DRUG).
Who is sponsoring clinical trial NCT05372354?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05372354 being conducted?
This trial has 17 study locations across Alabama, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05372354's enrollment target sits among peer trials
260 86th of 438 higher than 353 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI